Synthetic studies on ecteinascidin 743: Asymmetric synthesis of the versatile amino acid component

Tetrahedron Letters

Volumn 44, Issue 25, 2003, Pages 4635-4639

  Jin, Wei ^a   Williams, Robert M ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; ANTINEOPLASTIC ALKALOID; SAFRACIN; SAFRAMYCIN; TRABECTEDIN; TYROSINE DERIVATIVE; UNCLASSIFIED DRUG;

ALKYLATION; ARTICLE; ASYMMETRIC SYNTHESIS; CATALYSIS; CHEMICAL MODIFICATION; DRUG SYNTHESIS; HYDROGENATION; METHYLATION;

EID: 0037766229     PISSN: 00404039     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0040-4039(03)01082-7     Document Type: Article

References (35)

1. Rinehart K.L., Holt T.G., Fregeau N.L., Keifer P.A., Wilson G.R., Perun T.J., Sakai R., Thompson A.G., Stroh J.G., Shield L.S., Seigler D.S. J. Nat. Prod. 53:1990;771-792.
2. Rinehart K.L., Holt T.G., Fregeau N.L., Stroh J.G., Keifer P.A., Sun F., Li L.H., Martin D.G. J. Org. Chem. 55:1990;4512-4515.
3. Wright A.E., Forleo D.A., Gunawardana G.P., Gunasekera S.P., Koehn F.E., McConnell O.J. J. Org. Chem. 55:1990;4508-4512.
4. Guan Y., Sakai R., Rinehart K.L., Wang A.H.-J. J. Biomol. Struct. Dyn. 10:1993;793-818.
5. Zelek, L.; Yovine, A.; Etienne, B.; Jimeno, J.; Taamma, A.; Martín, C.; Spielmann, M.; Cvitkovic, E.; Misset, J. L. Ecteinacidin-743 in taxane/Antracycline pretreated advanced/metastatic breast cancer patients: preliminary results with the 24 h continuous infusion Q3 week schedule, presented at the American Society of Clinical Oncology, 36th Annual Meeting, New Orleans, 20-23 May, 2000. Abstract number 592 Delaloge, S.; Yovine, A.; Taamma, A.; Cottu, P.; Riofrio, M.; Raymond, E.; Brain, E.; Marty, M.; Jimeno, J.; Cvitkovic, E.; Misset, J. L. Preliminary evidence of activity of Ecteinacidin-743 (ET-743) in heavily pretreated patients with bone and soft tissue sarcomas, presented at the American Society of Clinical Oncology, 36th Annual Meeting, New Orleans, 20-23 May, 2000. Abstract number 2181 Le Cesne, A.; Judson, I.; Blay, J. Y.; Radford, J.; van Oosterom, A.; Lorigan, P.; Rodenhuis, E.; Donato Di Paoula, E.; Van Glabbeke, M.; Jimeno, J.; Verweij, J. Phase II of ET-743 in advance soft tissue sarcoma in adult: a STBSG-EORTC trial, presented at the American Society of Clinical Oncology, 36th Annual Meeting, New Orleans, 20-23 May 2000. Abstract number 2182.
6. Aune G.J., Furuta T., Pommier Y. Anti-Cancer Drugs. 13:2002;545-555.
7. Jin S., Gorfajn B., Faircloth G., Scotto K.W. Proc. Natl. Acad. Sci. USA. 97:2000;6775-6779.
8. Minuzzo M., Marchini S., Broggini M., Faircloth G., D'Incalci M., Mantovani R. Proc. Natl. Acad. Sci. USA. 97:2000;6780-6784.
9. Corey E.J., Gin D.Y., Kania R. J. Am. Chem. Soc. 118:1996;9202-9203.
10. Martinez E.J., Corey E.J., Owa T. Chem. Biol. 8:2001;1151-1160.
11. Takebayashi Y., Pourquier P., Zimonjic D.B., Nakayama K., Emmert S., Ueda T., Urasaki Y., Kanzaki A., Akiyama A.-I., Popescu N., Kraemer K.H., Pommier Y. Nature Med. 7:2001;961-966.
12. Zewail-Foote M., Li V.-S., Kohn H., Bearss D., Guzman M., Hurley L.H. Chem. Biol. 8:2001;1033-1049.
13. Martinez E.J., Owa T., Schreiber S.L., Corey E.J. Proc. Natl. Acad. Sci. USA. 96:1999;3496-3501.
14. Cuevas C., Pérez M., Martín M.J., Chicharro J.L., Fernández-Rivas C., Flores M., Francesch A., Gallego P., Zarzuelo M., de la Calle F., García J., Polanco C., Rodríguez I., Manzanares I. Org. Lett. 16:2000;2545-2548.
15. Endo A., Yanagisawa A., Abe M., Tohma S., Kan T., Fukuyama T. J. Am Chem. Soc. 124:2002;6552-6554.
16. Ikeda Y., Idemoto H., Hirayama F., Yamamoto K., Iwao K., Asao T., Munakata T. J. Antibiot. 36:1983;1279-1283.
17. Ikeda Y., Matsuki H., Ogawa T., Munakata T. J. Antibiot. 36:1983;1284-1289.
18. Arai T., Takahashi K., Kubo A., Nakahara S. Experientia. 36:1980;1025-1026.
19. Frincke J.M., Faulkner D.J. J. Am. Chem. Soc. 104:1982;265-269.
20. He H., Faulkner D.J. J. Org. Chem. 54:1989;5822-5824.
21. Davidson B.S. Tetrahedron Lett. 33:1992;3721-3724.
22. Parameswaran P.S., Naik C.G., Kamat S.Y., Pramanik B.N. Ind. J. Chem. 37B:1998;1258-1263.
23. Fontana A., Cavaliere P., Wahidulla S., Naik C.G., Cimino G. Tetrahedron. 56:2000;7305-7308.
24. For a review, see: Scott J.D., Williams R.M. Chem. Rev. 102:2002;1669-1730.
25. Both antipodes of 10 are commercially available from Aldrich Chemical Co.: 10, catalog #33,184-8; antipode of 10, catalog #33,181-3.
26. Williams R.M., Im M.-N. Tetrahedron Lett. 29:1988;6075-6078.
27. Williams R.M., Im M.-N. J. Am. Chem. Soc. 113:1991;9276-9286.
28. Williams R.M. Aldrichim. Acta. 25:1992;11-25.
29. Bender D.M., Williams R.M. J. Org. Chem. 62:1997;6690-6691.
30. Herberich B., Vazquez A., Kinugawa M., Jin W., Williams R.M. Tetrahedron Lett. 42:2001;543-546
31. Jin, W.; Metobo, S.; Williams, R. M., unpublished results.
32. 3, acetone 81% for two steps;
33. (b) Sinhababu, A. K.; Borchardt, R. T. Synth. Commun. 1983, 13, 677-683. The synthesis of 13 as described in the text is prepared according to the following scheme.
34. This amino acid salt is soluble in ether, and it thus proved expedient to take the crude salt on directly for the next step without further purification.
35. Abstract.